What are the safest and most effective medications for anxiety in a 72‑year‑old man with low‑PSA prostate cancer who is taking apalutamide, leuprolide (Eligard), and tamsulosin (Flomax), and who intermittently binge drinks alcohol?

Pharmacologic Management of Anxiety in This Patient

For this 72-year-old man with prostate cancer on apalutamide and intermittent alcohol binges, SSRIs are the safest first-line pharmacologic option, while benzodiazepines should be strictly avoided due to the high risk of addiction, falls, and dangerous interactions with alcohol. 1

Primary Recommendation: SSRIs as First-Line Treatment

The 2023 ASCO guideline for anxiety management in cancer survivors explicitly recommends physician-prescribed SSRIs as the pharmacologic intervention of choice, with selection informed by side-effect profiles, drug interactions, patient age, and preference 1. This is particularly critical in your patient given multiple complicating factors.

Why SSRIs Are Optimal Here:

• Age considerations: At 72 years, this patient falls into the age group where apalutamide shows increased Grade 3-4 adverse reactions (41% in 65-74 age group) 2, making medication tolerability paramount
• Fall risk: Apalutamide significantly increases fall risk in elderly patients (10% in 65-74 age group, 19% in ≥75 years) 2. Benzodiazepines would compound this risk dangerously
• Alcohol interaction: Intermittent binge drinking creates absolute contraindication to benzodiazepines due to synergistic CNS depression and addiction potential
• Cancer-related anxiety: Research shows 10.6% of men on androgen deprivation therapy develop new anxiety diagnoses 3, and anxiety remains stable over years in prostate cancer survivors 4

Critical Drug Interaction Considerations

Apalutamide is a strong CYP3A4 inducer 2, which may reduce levels of certain SSRIs metabolized by this pathway. Consider:

• Preferred SSRIs: Sertraline, citalopram, or escitalopram (less affected by CYP3A4 induction)
• Avoid: Fluoxetine (long half-life complicates alcohol interactions)
• Monitor closely for reduced SSRI efficacy due to apalutamide's enzyme induction

What NOT to Prescribe

Benzodiazepines Are Contraindicated

Despite being prescribed to 18.8% of anxious men on ADT in real-world practice 3, benzodiazepines are inappropriate here because:

• Synergistic respiratory depression with alcohol during binges
• Dramatically increased fall risk (already elevated 10% baseline from apalutamide) 2
• High addiction potential, especially problematic given existing alcohol use disorder pattern
• Cognitive impairment in elderly patients

The ASCO guideline mentions anxiolytics as an option 1, but this must be interpreted in context—the guideline does not account for intermittent alcohol binges, which fundamentally changes the risk-benefit calculation.

Stepped Care Algorithm

Step 1: Initiate SSRI + Non-Pharmacologic Interventions

• Start low-dose SSRI (e.g., sertraline 25-50 mg daily, escitalopram 5-10 mg daily)
• Simultaneously refer for cognitive behavioral therapy or acceptance and commitment therapy 1
• The guideline emphasizes that pharmacologic treatment should be combined with psychosocial interventions for moderate-to-severe anxiety 1

Step 2: Address Alcohol Use Disorder

• This is non-negotiable: Intermittent binge drinking requires concurrent substance use treatment
• Anxiety and alcohol use disorder are bidirectionally related; treating only anxiety will fail
• Consider addiction psychiatry or integrated behavioral health referral

Step 3: Monitor and Adjust (Monthly Until Stable)

• Assess SSRI adherence, side effects, and symptom relief 1
• Screen for worsening anxiety (use GAD-7 scores) 1
• Monitor for falls given apalutamide risk 2
• After 8 weeks, if inadequate response despite good compliance, adjust SSRI dose or switch agents 1

Step 4: Consider Taper When Appropriate

• If anxiety controlled and environmental stressors resolved, consider tapering SSRI 1
• This is particularly relevant as prostate cancer anxiety may improve with stable low PSA on apalutamide 5, 6

Common Pitfalls to Avoid

1. Prescribing benzodiazepines "just for breakthrough anxiety": This is the path to addiction and dangerous alcohol interactions
2. Ignoring the alcohol use disorder: Nearly half (47.7%) of anxious men on ADT receive no mental health treatment 3—don't contribute to this statistic
3. Failing to monitor for falls: This patient has 10% baseline fall risk from apalutamide alone 2
4. Overlooking drug interactions: Apalutamide's CYP3A4 induction may require higher SSRI doses 2
5. Medication-only approach: The guideline emphasizes combining pharmacologic with psychological interventions 1

Special Considerations for This Patient's Cancer Treatment

• Apalutamide continuation: His prostate cancer treatment should continue uninterrupted; anxiety management does not require oncologic treatment modification
• PSA monitoring: Achievement of PSA ≤0.2 ng/ml (occurs in 69% on apalutamide) 6 may reduce cancer-specific anxiety over time 4, 7
• ADT effects: Leuprolide (Eligard) itself may contribute to anxiety 8, 9, but this improves over time and is not an indication to stop cancer treatment

Bottom Line

Start an SSRI immediately, refer for CBT, and address the alcohol use disorder concurrently. Never prescribe benzodiazepines to this patient. The combination of advanced age, fall risk from apalutamide, and intermittent alcohol binges makes benzodiazepines dangerous regardless of anxiety severity. Monitor monthly until stable, and expect that anxiety may improve as PSA remains suppressed and the patient adjusts to his cancer diagnosis 1, 3, 4.